Eladocagene exuparvovec
Gene therapy / editing
Evidence outlook
Approved: AADC Deficiency
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signalSingle-arm, accepted for approval (FDA label)
Also approved (1)
- Patients aged 18 months and older with severe aromatic L-amino acid decarboxylase (AADC) deficiency (marketed as Upstaza; authorised under exceptional circumstances)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04903288 NCT04903288 · AADC Deficiency The study was open-label, non-randomized, and single-arm, with 13 participants receiving eladocagene exuparvovec plus standard care and no placebo or active comparator. Its main efficacy measure was a dopamine-related biomarker rather than a direct clinical outcome, so the reported change cannot establish treatment benefit through a controlled comparison. Registry: NCT04903288 | 2 | Change From Baseline in HVA Metabolite Level at the End of the Trial Phase (Baseline (Day 1), Week 8); Number of Participants With Adverse Events (AEs) Associated With the Surgical Administration of Eladocagene Exuparvovec Using the SmartFlow® MR-Compatible Ventricular Cannula (Baseline (Day 1) up to Week 8) 2023-05-22 | Results posted on ClinicalTrials.gov. Key figures are not recorded here. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Competitive landscape
Other AADC (aromatic L-amino acid decarboxylase) drugs
VGN-R09b. Compare all 2 AADC (aromatic L-amino acid decarboxylase) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Eladocagene Exuparvovec: this drug | Approved | Gene therapy / editing | AADC (aromatic L-amino acid decarboxylase) | Weak signal | No reviewed efficacy summary | |
| VGN-R09b | Phase 1/2(overall) | Gene therapy / editing | AADC (aromatic L-amino acid decarboxylase) | not yet graded | No reviewed efficacy summary |
Upcoming events
No upcoming readouts on record for this asset.